<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05613426</url>
  </required_header>
  <id_info>
    <org_study_id>HenanICE202204</org_study_id>
    <nct_id>NCT05613426</nct_id>
  </id_info>
  <brief_title>Effect of Very Early and Rapid Lowering Cholesterol With Evolocumab on Left Ventricular Remodeling in Patients With Anterior STEMI Undergoing Primary PCI</brief_title>
  <acronym>EVALUATE-STEMI</acronym>
  <official_title>Effect of Very Early and Rapid Lowering Cholesterol With Evolocumab on Left Ventricular Remodeling in Patients With Anterior ST Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention (EVALUATE-STEMI Trial): a Prospective, Multicenter, Open-label, Adjudicator-blinded, Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Henan Institute of Cardiovascular Epidemiology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Henan Institute of Cardiovascular Epidemiology</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      For patients with anterior ST elevation myocardial infarction (STEMI) undergoing primary&#xD;
      percutaneous coronary intervention (PCI), whether early application of proprotein convertase&#xD;
      subtilisin kexin type 9 (PCSK9) inhibitors to rapidly reduce low-density lipoprotein&#xD;
      cholesterol (LDL-C) before PCI could effectively inhibit left ventricular remodeling has been&#xD;
      rarely reported. The aim of this study was to investigate the effect of early application of&#xD;
      PCSK9 inhibitors Evolocumab to rapidly reduce LDL-C levels before primary PCI treatment on&#xD;
      left ventricular remodeling in STEMI patients.&#xD;
&#xD;
      Eligible patients were randomly randomized 1:1:1 to one of the following three groups&#xD;
      immediately after enrollment: (1) Intensive statin group: rosuvastatin 20 mg per day, in&#xD;
      addition to usual therapy; (2) Combined intensive statin and PCSK9 inhibitor group:&#xD;
      rosuvastatin 20 mg per day and subcutaneous injection of evolocumab 140 mg twice a month, for&#xD;
      at least 3 months, and preferably 6 months; (3) PCSK9 inhibitor alone group: subcutaneous&#xD;
      injection of evolocumab 140 mg, twice a month for at least 3 months and preferably 6 months.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 1, 2023</start_date>
  <completion_date type="Anticipated">June 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in left ventricular ejection fraction (LVEF)</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Echocardiography Core Laboratory, blinded analysis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in left ventricular end diastolic/systolic diameter</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Echocardiography Core Laboratory, blinded analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in left ventricular end diastolic/systolic volume</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Echocardiography Core Laboratory, blinded analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>A composite of cardiovascular death, recurrent myocardial infarction, ischemic stroke, and hospitalization for heart failure</measure>
    <time_frame>12 weeks, 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of LDL-C &lt; 1.4 mmol/L</measure>
    <time_frame>One week, 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thrombolysis in Myocardial Infarction (TIMI) flow grade</measure>
    <time_frame>TIMI flow in culprit coronary artery at first coronary angiography, and immediately after primary PCI within 12 hours of onset</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of troponin</measure>
    <time_frame>24 hours, 48 hours, and at hospital discharge, an average of 10 days after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events and serious adverse events</measure>
    <time_frame>At hospital discharge, an average of 10 days after randomization</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">330</enrollment>
  <condition>ST Elevation Myocardial Infarction (STEMI)</condition>
  <arm_group>
    <arm_group_label>Intensive statin group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rosuvastatin, 20 mg per day after randomization</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combined intensive statin and PCSK9 inhibitor group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Evolocumab, 140 mg twice a month after randomization, and Rosuvastatin, 20 mg per day after randomization</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PCSK9 inhibitor alone group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Evolocumab, 140 mg twice a month after randomization</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin 20 mg</intervention_name>
    <description>Very early use of Rosuvastatin before primary PCI in anterior STEMI</description>
    <arm_group_label>Combined intensive statin and PCSK9 inhibitor group</arm_group_label>
    <arm_group_label>Intensive statin group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Evolocumab 140 mg/1 ml Subcutaneous Solution [REPATHA]</intervention_name>
    <description>Very early use of Evolocumab before primary PCI in anterior STEMI</description>
    <arm_group_label>Combined intensive statin and PCSK9 inhibitor group</arm_group_label>
    <arm_group_label>PCSK9 inhibitor alone group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18-75 years&#xD;
&#xD;
          -  Persistent chest pain or chest discomfort&#xD;
&#xD;
          -  Onset within 12 hours&#xD;
&#xD;
          -  ST-segment elevation ≥0.1 millivolt in two adjacent precordial leads, or a new-onset&#xD;
             left bundle branch block with dynamic changes&#xD;
&#xD;
          -  Primary PCI is planned&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contraindications to Statins or PCSK9 inhibitors&#xD;
&#xD;
          -  Prior intravenous thrombolytic therapy&#xD;
&#xD;
          -  Prior use of Statins, PCSK9 inhibitors or Ezetimibe&#xD;
&#xD;
          -  Cardiogenic shock&#xD;
&#xD;
          -  Acute heart failure or pulmonary edema&#xD;
&#xD;
          -  Prior chronic heart failure&#xD;
&#xD;
          -  Severe hepatic and renal insufficiency (alanine aminotransferase ≥5 upper limit of&#xD;
             normal; estimated glomerular filtration rate &lt;30ml/min/1.73m2, or on dialysis)&#xD;
&#xD;
          -  Prolonged (&gt; 20 minutes) cardiopulmonary resuscitation&#xD;
&#xD;
          -  Definite mechanical complications (including ventricular septal perforation, or&#xD;
             rupture of the Papillary tendon bundle, or rupture of the left ventricular free wall)&#xD;
&#xD;
          -  Malignant arrhythmias that are difficult to control with drugs&#xD;
&#xD;
          -  Severe chronic obstructive pulmonary disease or respiratory failure&#xD;
&#xD;
          -  Severe infection&#xD;
&#xD;
          -  Neurological disorders&#xD;
&#xD;
          -  Bleeding history of cerebrovascular, gastrointestinal, respiratory, urinary or other&#xD;
             organs within the last month&#xD;
&#xD;
          -  Active bleeding or bleeding diatheses&#xD;
&#xD;
          -  Use of anticoagulants&#xD;
&#xD;
          -  Malignant tumors or other pathophysiological conditions with an expected survival time&#xD;
             of less than 1 year&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>You Zhang, Doctor</last_name>
    <phone>+86 37158681037</phone>
    <email>youzhangww@hotmail.com</email>
  </overall_contact>
  <verification_date>February 2023</verification_date>
  <study_first_submitted>October 18, 2022</study_first_submitted>
  <study_first_submitted_qc>November 4, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 14, 2022</study_first_posted>
  <last_update_submitted>February 1, 2023</last_update_submitted>
  <last_update_submitted_qc>February 1, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">February 2, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Henan Institute of Cardiovascular Epidemiology</investigator_affiliation>
    <investigator_full_name>Chuanyu Gao</investigator_full_name>
    <investigator_title>Vice President, Chief of Cardiology Department</investigator_title>
  </responsible_party>
  <keyword>ST Elevation Myocardial Infarction</keyword>
  <keyword>percutaneous coronary intervention</keyword>
  <keyword>PCSK9 Inhibitors</keyword>
  <keyword>left ventricular remodeling</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Ventricular Remodeling</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
    <mesh_term>Evolocumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

